Drug details

Brixadi (buprenorphine extended-release injection)

type of Analgesics, Opioid Partial Agonist

Brixadi (buprenorphine) is a partial opioid agonist indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. Brixadi should be used as part of a complete treatment plan that includes counseling and psychosocial support.

This drug may have the following side effects:

• nausea,
• vomiting,
• diarrhea,
• constipation,
• headache,
• insomnia,
• fast heart rate,
• urinary tract infection (UTI),
• upper respiratory tract infection
• injection site reactions (pain, redness, itching, swelling),
• joint pain, and
• anxiety.

The following drugs are related to Brixadi, either as a replacement or used together:

• Belbuca (buprenorphine buccal film)
• Buprenex (buprenorphine)
• Sublocade (buprenorphine injection for subcutaneous use)
• Butrans (buprenorphine transdermal)
• Opvee (nalmefene nasal spray)
• Narcan (naloxone hydrochloride injection)
• Narcan Nasal (naloxone hydrochloride nasal spray)
• Revia (naltrexone)
• Vivitrol (naltrexone xr inj)